tiprankstipranks
Trending News
More News >
Inhibitor Therapeutics Inc. (INTI)
OTHER OTC:INTI
US Market

Inhibitor Therapeutics (INTI) Income Statement

Compare
30 Followers

Inhibitor Therapeutics Income Statement

Last quarter (Q3 2025), Inhibitor Therapeutics's total revenue was $0.00, a decrease of ― from the same quarter last year. In Q3, Inhibitor Therapeutics's net income was $-712.18K. See Inhibitor Therapeutics’s key income statements, including revenue, expenses, profit, and income.
Income Statement
Dec 24Dec 23Dec 22Dec 21Dec 20
Total Revenue
$ 0.00$ 0.00$ 0.00$ 0.00$ 0.00
Gross Profit
$ 0.00$ 0.00$ 0.00$ 0.00$ 0.00
Operating Expenses
$ 3.66M$ 3.40M$ 657.93K$ 325.39K$ 1.06M
Depreciation and Amortization
$ 3.66M$ 3.40M$ 657.93K$ 325.39K$ 1.06M
EBITDA
$ 318.00K$ 378.84K$ -74.00$ -325.00K$ -1.06M
Operating Income
$ -3.66M$ -3.40M$ -658.00K$ -325.00K$ -1.06M
Other Income/Expenses
$ 318.21K$ 378.84K$ 12.82M$ 26.76K$ 1.07K
Pretax Income
$ -3.34M$ -3.03M$ 12.16M$ -299.00K$ -1.06M
Net Income
$ -3.34M$ -3.03M$ 12.11M$ -299.00K$ -1.06M
Per Share Metrics
Basic EPS
$ -0.02$ -0.02$ 0.03$ 0.00$ 0.00
Diluted EPS
$ -0.02$ -0.02$ 0.03$ 0.00$ 0.00
Weighted Average Shares Outstanding
172.26M 151.31M 366.18M 376.25M 371.93M
Weighted Average Shares Outstanding (Diluted)
172.26M 171.95M 367.78M 376.25M 371.93M
Currency in USD

Inhibitor Therapeutics Earnings and Revenue History